Literature DB >> 27513584

Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention.

Michael G Wheaton1, Joseph K Carpenter, Eyal Kalanthroff, Edna B Foa, Helen Blair Simpson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27513584      PMCID： PMC5031481          DOI： 10.1159/000445356

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN： 0033-3190            Impact factor:   17.659


× No keyword cloud information.
  9 in total

1.  Preferences.

Authors:  Joshua K Swift; Jennifer L Callahan; Barbara M Vollmer
Journal:  J Clin Psychol       Date:  2011-02

2.  Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Authors:  Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Jonathan D Huppert; Shawn Cahill; Michael J Maher; Carmen P McLean; James Bender; Sue M Marcus; Monnica T Williams; Jamie Weaver; Donna Vermes; Page E Van Meter; Carolyn I Rodriguez; Mark Powers; Anthony Pinto; Patricia Imms; Chang-Gyu Hahn; Raphael Campeas
Journal:  JAMA Psychiatry       Date:  2013-11       Impact factor: 21.596

3.  Patient Preferences and Acceptability of Evidence-Based and Novel Treatments for Obsessive-Compulsive Disorder.

Authors:  Sapana R Patel; Hanga Galfavy; Marcia B Kimeldorf; Lisa B Dixon; Helen Blair Simpson
Journal:  Psychiatr Serv       Date:  2016-10-17       Impact factor: 3.084

4.  Patient preferences for obsessive-compulsive disorder treatment.

Authors:  Sapana R Patel; Helen Blair Simpson
Journal:  J Clin Psychiatry       Date:  2010-11       Impact factor: 4.384

5.  A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.

Authors:  C J McDougle; C N Epperson; G H Pelton; S Wasylink; L H Price
Journal:  Arch Gen Psychiatry       Date:  2000-08

6.  Treatment preferences of psychotherapy patients with chronic PTSD.

Authors:  John C Markowitz; Kevin B Meehan; Eva Petkova; Yihong Zhao; Page E Van Meter; Yuval Neria; Hayley Pessin; Yasmin Nazia
Journal:  J Clin Psychiatry       Date:  2016-03       Impact factor: 4.384

7.  Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.

Authors:  Carmen P McLean; Laurie J Zandberg; Page E Van Meter; Joseph K Carpenter; Helen Blair Simpson; Edna B Foa
Journal:  J Clin Psychiatry       Date:  2015-12       Impact factor: 4.384

8.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11

9.  Treatment response, symptom remission, and wellness in obsessive-compulsive disorder.

Authors:  Samantha G Farris; Carmen P McLean; Page E Van Meter; Helen Blair Simpson; Edna B Foa
Journal:  J Clin Psychiatry       Date:  2013-07       Impact factor: 4.384
  9 in total
  2 in total

1.  Association of Patient Treatment Preference With Dropout and Clinical Outcomes in Adult Psychosocial Mental Health Interventions: A Systematic Review and Meta-analysis.

Authors:  Emma Windle; Helena Tee; Alina Sabitova; Nikolina Jovanovic; Stefan Priebe; Catherine Carr
Journal:  JAMA Psychiatry       Date:  2020-03-01       Impact factor: 21.596

2.  Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Brian P Brennan; Lorrin Koran; Carol A Mathews; Gerald Nestadt; Michele Pato; Katharine A Phillips; Carolyn I Rodriguez; H Blair Simpson; Petros Skapinakis; Dan J Stein; Eric A Storch
Journal:  Psychiatry Res       Date:  2021-03-04       Impact factor: 11.225
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.